{
  "items": "45",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "CERO SEC Filings - CERo Therapeutics 10-K, 10-Q, 8-K Forms",
      "url": "https://www.stocktitan.net/sec-filings/CERO/page-3.html",
      "time_published": "20251224T211054",
      "authors": [
        "NULL"
      ],
      "summary": "This page provides a comprehensive resource for investors to access CERo Therapeutics (CERO) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. Stock Titan uses AI to simplify these complex documents, offering concise explanations and real-time alerts on significant events and executive stock movements. The article highlights recent filings such as a 10-Q disclosing financial struggles and an S-1 for IPO registration.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.935447"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.808249"
        },
        {
          "topic": "finance",
          "relevance_score": "0.717388"
        },
        {
          "topic": "ipo",
          "relevance_score": "0.612924"
        }
      ],
      "overall_sentiment_score": -0.402942,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.388313",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Cero Therapeutics shareholders approve equity plan amendment and reverse stock split",
      "url": "https://www.investing.com/news/sec-filings/cero-therapeutics-shareholders-approve-equity-plan-amendment-and-reverse-stock-split-93CH-4418159",
      "time_published": "20251220T030927",
      "authors": [
        "Investing.com"
      ],
      "summary": "Cero Therapeutics Holdings, Inc. (NASDAQ:CERO) shareholders have approved an amendment to the company's equity incentive plan, increasing the shares available for issuance by 32,000,000. Additionally, shareholders sanctioned a reverse stock split, with a ratio ranging from one-for-forty to one-for-one-hundred-fifty, and approved the issuance of common stock from the conversion of Series E preferred stock. These approvals were made at a special meeting, as detailed in a press release and SEC filing.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_headline_rolled_69x52._800x533_L_1419494221.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.926667"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.703073"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.634196"
        }
      ],
      "overall_sentiment_score": 0.140048,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.133725",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cero Therapeutics shareholders approve equity plan amendment and reverse stock split",
      "url": "https://ng.investing.com/news/sec-filings/cero-therapeutics-shareholders-approve-equity-plan-amendment-and-reverse-stock-split-93CH-2263445",
      "time_published": "20251220T000919",
      "authors": [
        "Investing.com"
      ],
      "summary": "Cero Therapeutics Holdings, Inc. (NASDAQ:CERO) shareholders approved an amendment to the company's 2024 Equity Incentive Plan, increasing available shares for issuance by 32,000,000. Additionally, they authorized a reverse stock split at a ratio between one-for-forty to one-for-one-hundred-fifty, and approved the issuance of shares to convert Series E preferred stock. These actions aim to advance Cero Therapeutics' financial and clinical progress, alongside recent stock purchase agreements and advancements in their Phase 1 leukemia trial.",
      "banner_image": "https://i-invdn-com.investing.com/news/World_News_8_800x533_L_1420026210.jpg",
      "source": "Investing.com Nigeria",
      "category_within_source": "General",
      "source_domain": "Investing.com Nigeria",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.909848"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.707938"
        }
      ],
      "overall_sentiment_score": 0.021854,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.044623",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)",
      "url": "https://www.globenewswire.com/news-release/2025/12/17/3206929/0/en/cero-therapeutics-provides-clinical-update-on-phase-1-clinical-trial-of-cer-1236-in-aml-certaint-1.html",
      "time_published": "20251217T131135",
      "authors": [],
      "summary": "CERo Therapeutics announced a clinical update on its Phase 1 CertainT-1 trial for CER-1236 in patients with acute myeloid leukemia (AML). The company completed the DLT observation period for Cohort 1 and has dosed the first patient in Cohort 2 at a higher cell level, who also completed DLT observation. Additionally, a patient in Cohort 1 received an additional dose and remains under study, as CERo continues to focus on safety data collection during the dose-escalation phase.",
      "banner_image": "https://ml.globenewswire.com/media/MGU1NjAyYjQtYWUzNS00Y2RiLTgyNTYtYjk0MTk3ZjBhZDA1LTUwMDEyNDM5MC0yMDI1LTEyLTE3LWVu/tiny/CERo-Therapeutics-Holdings-Inc.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.944358"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.649818"
        }
      ],
      "overall_sentiment_score": 0.486171,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.459122",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "CERo Therapeutics (OTCQB: CERO) starts OTCQB trading, eyes potential uplist",
      "url": "https://www.stocktitan.net/news/CERO/ce-ro-therapeutics-announces-trading-on-otcqb-kek491kfzgbr.html",
      "time_published": "20251205T040951",
      "authors": [],
      "summary": "CERo Therapeutics (OTCQB: CERO) announced its shares began trading on the OTCQB market on December 2, 2025, with the company evaluating options for a major exchange uplisting to enhance liquidity and investor accessibility. The company also reiterated its focus on advancing its Phase 1 trial for CER-1236 for AML, noting a significant increase in the starting dosage for the current cohort. The news led to a 14.29% gain in CERO's stock price on the day of the announcement.",
      "banner_image": "https://ml.globenewswire.com/media/NDYwZTViMDYtNDBhYy00OGQ5LWFkZGUtMzdhOTkzZjhjZGJkLTUwMDEyNDM5MC0yMDI1LTEyLTAyLWVu/tiny/CERo-Therapeutics-Holdings-Inc.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.928663"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.810499"
        },
        {
          "topic": "ipo",
          "relevance_score": "0.718633"
        },
        {
          "topic": "finance",
          "relevance_score": "0.602353"
        }
      ],
      "overall_sentiment_score": 0.227266,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.214126",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Cero Therapeutics enters new stock purchase agreement for up to $14.6 million",
      "url": "https://www.investing.com/news/sec-filings/cero-therapeutics-enters-new-stock-purchase-agreement-for-up-to-146-million-93CH-4386127",
      "time_published": "20251203T035414",
      "authors": [
        "Investing.com"
      ],
      "summary": "Cero Therapeutics Holdings, Inc. (NASDAQ:CERO) announced a new stock purchase agreement allowing it to issue and sell up to $14.6 million of common stock, continuing its existing equity line program. This agreement aims to help the company reach a cumulative total of $25 million in stock issuances, despite its stock currently trading below its Fair Value. The company can direct the institutional investor to purchase shares under specific conditions, with limitations on individual transaction size and investor ownership.",
      "banner_image": "https://i-invdn-com.investing.com/news/World_News_10_800x533_L_1420026292.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.820901"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.725476"
        }
      ],
      "overall_sentiment_score": 0.192672,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.108013",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.575017",
          "ticker_sentiment_score": "0.241577",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "CERo Therapeutics Enters New $14.6M Stock Agreement",
      "url": "https://www.tipranks.com/news/company-announcements/cero-therapeutics-enters-new-14-6m-stock-agreement",
      "time_published": "20251203T035414",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "CERo Therapeutics Holdings (CERO) has entered a new stock purchase agreement on November 26, 2025, to sell up to $14.6 million in common stock to an institutional investor. This agreement is part of a larger effort to raise $25 million and includes provisions to maintain regulatory compliance regarding the investor's ownership percentage. The company, which operates in the biotechnology industry, aims to strengthen its financial position and capital-raising flexibility through this strategic move.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2127549605-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.885265"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.793458"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.729493"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.620873"
        }
      ],
      "overall_sentiment_score": 0.118626,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.999331",
          "ticker_sentiment_score": "0.103331",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERo Therapeutics Announces Trading on OTCQB Market",
      "url": "https://www.globenewswire.com/news-release/2025/12/02/3197791/0/en/CERo-Therapeutics-Announces-Trading-on-OTCQB-Market.html",
      "time_published": "20251202T073000",
      "authors": [
        "NULL"
      ],
      "summary": "CERo Therapeutics Holdings, Inc. (OTCQB: CERO) announced that its shares commenced trading on the OTCQB market as of December 2, 2025, at 8:00 AM ET. The company continues to explore options for up-listing to a major exchange to enhance liquidity and investor accessibility. CEO Chris Ehrlich emphasized the company's commitment to advancing its Phase 1 clinical trial for CER-1236 AML and maximizing shareholder value.",
      "banner_image": "https://ml.globenewswire.com/media/NDYwZTViMDYtNDBhYy00OGQ5LWFkZGUtMzdhOTkzZjhjZGJkLTUwMDEyNDM5MC0yMDI1LTEyLTAyLWVu/tiny/CERo-Therapeutics-Holdings-Inc.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "ipo",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.922559"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.837133"
        }
      ],
      "overall_sentiment_score": 0.313441,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.310628",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "CERo Therapeutics Delays Quarterly Report Filing",
      "url": "https://www.tipranks.com/news/company-announcements/cero-therapeutics-delays-quarterly-report-filing",
      "time_published": "20251118T071020",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "CERo Therapeutics Holdings (CERO) has delayed filing its Form 10-Q for the financial period ending September 30, 2025, primarily due to finalization of accounting for recent transactions and ongoing auditor review. The company expects to file within five calendar days of the original due date and has reported a preliminary net loss of $4.4 million for the quarter. An analyst currently rates CERO as a Hold with a $0.10 price target.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1423187486-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.948208"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.826153"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.725173"
        }
      ],
      "overall_sentiment_score": 0.045183,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.344632",
          "ticker_sentiment_score": "0.013499",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERo Therapeutics Holdings (CERO) Price Target Increased by 33.33% to 30.60",
      "url": "https://www.nasdaq.com/articles/cero-therapeutics-holdings-cero-price-target-increased-3333-3060",
      "time_published": "20251117T032800",
      "authors": [
        "George Maybach"
      ],
      "summary": "The average one-year price target for CERo Therapeutics Holdings (OTCPK:CERO) has significantly increased by 33.33% to $30.60 per share, up from $22.95. This new target is an average of analyst estimates ranging from $30.30 to $31.50 and represents a substantial 32,076.66% increase from the last closing price of $0.10. Institutional holdings have seen an increase in the number of funds reporting positions, though total shares owned by institutions decreased in the last three months.",
      "banner_image": null,
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.904384"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.831128"
        }
      ],
      "overall_sentiment_score": 0.518711,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.508077",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "CERo Therapeutics (OTC PINK: CERO) lists on OTC Pink, exploring uplist options",
      "url": "https://www.stocktitan.net/news/CERO/ce-ro-therapeutics-announces-listing-on-otc-20uvdjvq4btj.html",
      "time_published": "20251110T070935",
      "authors": [
        "NULL"
      ],
      "summary": "CERo Therapeutics (OTC PINK: CERO) announced that its shares continue to trade on the OTC PINK market as of October 31, 2025, and the company is actively evaluating uplist options to improve liquidity and accessibility for investors. Concurrently, CERo highlighted progress in its Phase 1 AML program for CER-1236, initiating Cohort 2 with an FDA-approved significant dosage increase. The company reassures shareholders that operations continue as usual, focusing on advancing its clinical trials and maximizing shareholder value despite the listing change.",
      "banner_image": "https://ml.globenewswire.com/media/MGEzNTNjZWItODRlZC00NDhjLTljY2UtYWU3Mzc2ODY1YjkxLTUwMDEyNDM5MC0yMDI1LTExLTAzLWVu/tiny/CERo-Therapeutics-Holdings-Inc.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "ipo",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.920872"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.812656"
        }
      ],
      "overall_sentiment_score": 0.323632,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.301312",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "D. Boral Capital Maintains CERo Therapeutics Holdings (CERO) Buy Recommendation",
      "url": "https://www.nasdaq.com/articles/d-boral-capital-maintains-cero-therapeutics-holdings-cero-buy-recommendation-0",
      "time_published": "20251108T035414",
      "authors": [
        "George Maybach"
      ],
      "summary": "D. Boral Capital has reiterated a Buy recommendation for CERo Therapeutics Holdings (CERO). Analysts predict a significant upside, with an average one-year price target of $45.90, representing a 2,183.58% increase from its current closing price. Institutional ownership in CERO has seen a decrease in the last quarter, though some major holders like Parallel Advisors maintain substantial positions.",
      "banner_image": "NULL",
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.811975"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.722401"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.903006"
        }
      ],
      "overall_sentiment_score": 0.514072,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.486217",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "CERo Therapeutics (NASDAQ: CERO) denied over $2.5M equity rule; suspended Oct. 31",
      "url": "https://www.stocktitan.net/news/CERO/ce-ro-therapeutics-announces-receipt-of-nasdaq-panel-qy2dpye0qtyl.html",
      "time_published": "20251108T035414",
      "authors": [],
      "summary": "CERo Therapeutics (NASDAQ: CERO) has been denied continued listing by a Nasdaq Hearings Panel due to non-compliance with the minimum stockholders' equity rule, with trading set to be suspended on October 31, 2025. This decision follows a retroactive re-evaluation of its equity after a discounted sale of marketable securities. Despite this, the company plans to appeal to the Nasdaq Council, seek trading on the OTC Markets, and continue its clinical trials, including the dosing of CER-1236.",
      "banner_image": "https://ml.globenewswire.com/media/YTAyNjM1NzEtODU0Yi00NjQwLWJjYzItMzVlMmI5ODlhNzExLTUwMDEyNDM5MC0yMDI1LTEwLTI5LWVu/tiny/CERo-Therapeutics-Holdings-Inc.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.920201"
        }
      ],
      "overall_sentiment_score": 0.025865,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.322615",
          "ticker_sentiment_score": "0.017014",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "D. Boral Capital Maintains CERo Therapeutics Holdings (CERO) Buy Recommendation",
      "url": "https://www.nasdaq.com/articles/d-boral-capital-maintains-cero-therapeutics-holdings-cero-buy-recommendation-1",
      "time_published": "20251030T080200",
      "authors": [
        "George Maybach"
      ],
      "summary": "D. Boral Capital has maintained a Buy recommendation for CERo Therapeutics Holdings (CERO). Analysts predict a significant upside of 1,182.12% with an average price target of $22.95/share. Fund sentiment shows a decrease in owners but an increase in average portfolio weight dedicated to CERO, with institutional ownership declining by 52.55% in the last quarter.",
      "banner_image": "NULL",
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.904365"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.838362"
        },
        {
          "topic": "finance",
          "relevance_score": "0.740506"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.602734"
        }
      ],
      "overall_sentiment_score": 0.474032,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.470797",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "CERo Therapeutics Announces Receipt of Nasdaq Panel Determination",
      "url": "https://www.globenewswire.com/news-release/2025/10/29/3176992/0/en/CERo-Therapeutics-Announces-Receipt-of-Nasdaq-Panel-Determination.html",
      "time_published": "20251029T192200",
      "authors": [],
      "summary": "CERo Therapeutics announced receipt of a Nasdaq Hearings Panel determination to deny the Company\u2019s request to continue its common stock listing on Nasdaq, citing non-compliance with the Equity Rule. Trading of CERo's shares will be suspended on October 31, 2025, and the company plans to appeal the decision, seek trading on OTC Markets, and continue clinical operations. CERo also detailed its efforts to regain compliance, including a financing round and successful clinical trial observations for CER-1236.",
      "banner_image": null,
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.934011"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.825142"
        },
        {
          "topic": "finance",
          "relevance_score": "0.722810"
        }
      ],
      "overall_sentiment_score": -0.916569,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.906736",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "CERo Therapeutics Holdings, Inc. Announces Nasdaq Suspension and Plans for OTC Trading Amid Compliance Challenges",
      "url": "https://www.quiverquant.com/news/CERo+Therapeutics+Holdings%2C+Inc.+Announces+Nasdaq+Suspension+and+Plans+for+OTC+Trading+Amid+Compliance+Challenges",
      "time_published": "20251029T113000",
      "authors": [],
      "summary": "CERo Therapeutics Holdings, Inc. faces Nasdaq delisting due to non-compliance with the $2.5 million stockholders' equity rule, with trading of its common stock to be suspended on October 31. The company plans to appeal Nasdaq's decision and explore trading on OTC Markets, although this may impact liquidity. Despite these challenges, CERo is actively pursuing financing alternatives and advancing clinical trials for its lead candidate, CER-1236, which has shown promising early results.",
      "banner_image": "https://quiverquant.com/images/cero_rect_new.png",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.940242"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.916419"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.846788"
        },
        {
          "topic": "finance",
          "relevance_score": "0.745677"
        }
      ],
      "overall_sentiment_score": -0.613232,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.648493",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "CERo Therapeutics Completes First Tranche of $7 Million Financing to Support Clinical Development and Nasdaq Compliance | CERO Stock News",
      "url": "https://www.quiverquant.com/news/CERo+Therapeutics+Completes+First+Tranche+of+%247+Million+Financing+to+Support+Clinical+Development+and+Nasdaq+Compliance",
      "time_published": "20251021T122100",
      "authors": [
        "NULL"
      ],
      "summary": "CERo Therapeutics has completed the first tranche of a $7 million financing, raising $2.3 million from existing shareholders to extend its cash runway and maintain Nasdaq compliance. The company is advancing its Phase 1 clinical trial for CER-1236, an innovative T cell therapy for acute myeloid leukemia, by administering a third infusion to a patient in the first cohort to gather further safety and dosing data. This financing and clinical progress occur amidst challenging financial conditions, with the company expressing gratitude for continued shareholder support.",
      "banner_image": "https://www.quiverquant.com/images/cero_rect_new.png",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.911325"
        }
      ],
      "overall_sentiment_score": 0.445956,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.420998",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Cero Therapeutics amends purchase agreement, completes initial closing for $2.25 million - Investing.com Philippines",
      "url": "https://ph.investing.com/news/sec-filings/cero-therapeutics-amends-purchase-agreement-completes-initial-closing-for-225-million-93CH-2042639",
      "time_published": "20251016T225051",
      "authors": [],
      "summary": "This article from Investing.com Philippines reports that Cero Therapeutics has amended a purchase agreement and completed an initial closing for $2.25 million. However, the visible content also indicates an application error, suggesting the full article text is not loading correctly.",
      "banner_image": null,
      "source": "Investing.com Philippines",
      "category_within_source": "General",
      "source_domain": "Investing.com Philippines",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.808990"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.734157"
        }
      ],
      "overall_sentiment_score": 0.000518,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.322897",
          "ticker_sentiment_score": "0.047247",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERo Therapeutics Expands Securities Purchase Agreement - TipRanks",
      "url": "https://www.tipranks.com/news/company-announcements/cero-therapeutics-expands-securities-purchase-agreement",
      "time_published": "20251016T205635",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "CERo Therapeutics Holdings amended its Securities Purchase Agreement, increasing the initial closing of its offering by $500,000 to approximately $2.25 million, for a total offering target of $7 million. The company issued 3,816 shares of Series E Preferred Stock in the initial closing, with the remaining $4.75 million expected in future closings. The transaction was a private offering and an analyst has a Buy rating with a $30.00 price target on CERO stock.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1423187486-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.743608"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.645361"
        }
      ],
      "overall_sentiment_score": 0.041545,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.340568",
          "ticker_sentiment_score": "0.011380",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cero Therapeutics amends purchase agreement, completes initial closing for $2.25 million - Investing.com India",
      "url": "https://in.investing.com/news/sec-filings/cero-therapeutics-amends-purchase-agreement-completes-initial-closing-for-225-million-93CH-5049640",
      "time_published": "20251016T204156",
      "authors": [],
      "summary": "This article reports that Cero Therapeutics has amended a purchase agreement and completed an initial closing for $2.25 million. However, the full content of the article is unavailable due to an application error. Thus, detailed information regarding the transaction is not provided.",
      "banner_image": null,
      "source": "Investing.com India",
      "category_within_source": "General",
      "source_domain": "Investing.com India",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.926248"
        },
        {
          "topic": "finance",
          "relevance_score": "0.541905"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.420863"
        }
      ],
      "overall_sentiment_score": 0.045091,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.300270",
          "ticker_sentiment_score": "0.017266",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cero Therapeutics amends purchase agreement, completes initial closing for $2.25 million - Investing.com",
      "url": "https://www.investing.com/news/sec-filings/cero-therapeutics-amends-purchase-agreement-completes-initial-closing-for-225-million-93CH-4293259",
      "time_published": "20251016T204002",
      "authors": [],
      "summary": "Cero Therapeutics has completed an initial closing of a purchase agreement for $2.25 million, following an amendment to the original terms. The article title suggests this concerns the company's financial activities and fundraising efforts. However, due to an application error, the full content of the article is not available.",
      "banner_image": null,
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.705977"
        }
      ],
      "overall_sentiment_score": 0.04371,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.301321",
          "ticker_sentiment_score": "0.015530",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cero Therapeutics amends purchase agreement, completes initial closing for $2.25 million - Investing.com",
      "url": "https://m.investing.com/news/sec-filings/cero-therapeutics-amends-purchase-agreement-completes-initial-closing-for-225-million-93CH-4293259?ampMode=1",
      "time_published": "20251016T203100",
      "authors": [
        "Investing.com"
      ],
      "summary": "Cero Therapeutics Holdings, Inc. amended its Securities Purchase Agreement, adding a buyer and increasing its initial closing proceeds to $2.25 million, with the total aggregate funding remaining at up to $7 million. The company issued 3,816 shares of Series E Preferred Stock in the initial closing. This news follows recent updates on their Phase 1 clinical trial for CER-1236 and patent protections.",
      "banner_image": "https://i-invdn-com.investing.com/news/World_News_9_M_1440052127.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.718406"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.504347"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.438769"
        }
      ],
      "overall_sentiment_score": 0.017995,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.341201",
          "ticker_sentiment_score": "0.049001",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025 - The Manila Times",
      "url": "https://www.manilatimes.net/2025/10/15/tmt-newswire/globenewswire/cero-therapeutics-to-participate-in-stem-cell-therapy-panel-at-the-maxim-growth-summit-2025/2201376",
      "time_published": "20251015T124918",
      "authors": [],
      "summary": "CERo Therapeutics announced its participation in a Stem Cell Therapy Panel at the upcoming Maxim Growth Summit 2025. Dr. Daniel J. Teper, CEO of CERo Therapeutics, will be a featured speaker, highlighting the company's advancements in stem cell therapy. The summit provides a platform for companies to discuss growth opportunities and innovations in various sectors.",
      "banner_image": null,
      "source": "The Manila Times",
      "category_within_source": "General",
      "source_domain": "The Manila Times",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.947628"
        }
      ],
      "overall_sentiment_score": 0.021484,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.300643",
          "ticker_sentiment_score": "0.016707",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERo Therapeutics (NASDAQ:CERO) Receives Buy Rating from D. Boral Capital",
      "url": "https://www.defenseworld.net/2025/10/14/cero-therapeutics-nasdaqcero-receives-buy-rating-from-d-boral-capital.html",
      "time_published": "20251014T185333",
      "authors": [
        "Defense World Staff"
      ],
      "summary": "D. Boral Capital has issued a \"buy\" rating for CERo Therapeutics (NASDAQ:CERO), upgrading it from a \"hold\" rating earlier in the year. The article highlights that institutional investors are increasing their positions in CERo Therapeutics, with Armistice Capital LLC recently acquiring new shares. CERo Therapeutics is an immunotherapy company focused on developing engineered T cell therapeutics for cancer treatment, based in South San Francisco, California.",
      "banner_image": null,
      "source": "Defense World",
      "category_within_source": "General",
      "source_domain": "Defense World",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.928754"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.816624"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.722174"
        },
        {
          "topic": "finance",
          "relevance_score": "0.622174"
        }
      ],
      "overall_sentiment_score": 0.032743,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.327580",
          "ticker_sentiment_score": "0.032304",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERo Therapeutics Enters Securities Purchase Agreement - TipRanks",
      "url": "https://www.tipranks.com/news/company-announcements/cero-therapeutics-enters-securities-purchase-agreement",
      "time_published": "20251014T133057",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "CERo Therapeutics Holdings (CERO) entered a Securities Purchase Agreement on October 14, 2025, to issue up to 9,750 shares of its Series E convertible preferred stock for up to $7 million. The agreement includes consent from Series C and D stockholders for the Series E issuance, alongside a reduction in conversion prices for Series C and D stocks. This Series E Preferred Stock will rank senior to most other company stocks and offers various investor protections and rights, including conversion, purchase, and redemption options.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1061972606-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.708948"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.539681"
        }
      ],
      "overall_sentiment_score": 0.025636,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.331847",
          "ticker_sentiment_score": "0.026236",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERO: Analyst Maintains Buy Rating with $30 Target | CERO Stock News - GuruFocus",
      "url": "https://www.gurufocus.com/news/3140706/cero-analyst-maintains-buy-rating-with-30-target-cero-stock-news",
      "time_published": "20251013T153752",
      "authors": [
        "GuruFocus News"
      ],
      "summary": "D. Boral Capital analyst Jason Kolbert has maintained a Buy rating for CERo Therapeutics Holdings (CERO) with a consistent $30 price target, a rating held for several months. This sustained analyst sentiment suggests a stable outlook for CERO, an immunotherapy company developing engineered T cell therapeutics for cancer. Wall Street analysts forecast an average target price of $45.00 for CERO, significantly above its current price of $3.28, with an \"Outperform\" status based on consensus recommendations.",
      "banner_image": null,
      "source": "GuruFocus",
      "category_within_source": "General",
      "source_domain": "GuruFocus",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.945975"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.749258"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.534396"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.540879"
        }
      ],
      "overall_sentiment_score": 0.027097,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.340459",
          "ticker_sentiment_score": "0.029555",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERo Therapeutics completes first cohort in leukemia treatment trial - Investing.com India",
      "url": "https://in.investing.com/news/company-news/cero-therapeutics-completes-first-cohort-in-leukemia-treatment-trial-93CH-5041270",
      "time_published": "20251013T125450",
      "authors": [],
      "summary": "The article states that CERo Therapeutics has completed the first cohort in its leukemia treatment trial. However, the full content of the article is not available, as an application error prevented it from loading.",
      "banner_image": null,
      "source": "Investing.com India",
      "category_within_source": "General",
      "source_domain": "Investing.com India",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.908134"
        }
      ],
      "overall_sentiment_score": 0.03638,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.307588",
          "ticker_sentiment_score": "0.046221",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERo Therapeutics completes first cohort in AML clinical trial - Investing.com India",
      "url": "https://in.investing.com/news/company-news/cero-therapeutics-completes-first-cohort-in-aml-clinical-trial-93CH-5041282",
      "time_published": "20251013T125450",
      "authors": [],
      "summary": "This article reports that CERo Therapeutics has completed the first cohort in its clinical trial for Acute Myeloid Leukemia (AML). However, due to a client-side exception, the full details of this significant achievement are not accessible. The nature of the exception suggests a technical issue prevented the complete article from loading.",
      "banner_image": null,
      "source": "Investing.com India",
      "category_within_source": "General",
      "source_domain": "Investing.com India",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.914781"
        }
      ],
      "overall_sentiment_score": 0.000794,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.303603",
          "ticker_sentiment_score": "0.020639",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERo Therapeutics completes first cohort in AML clinical trial By Investing.com - Investing.com South Africa",
      "url": "https://za.investing.com/news/company-news/cero-therapeutics-completes-first-cohort-in-aml-clinical-trial-93CH-3916668",
      "time_published": "20251013T125439",
      "authors": [
        "Investing.com"
      ],
      "summary": "The provided article content reports an application error encountered when trying to load za.investing.com. Due to this error, the actual news content about CERo Therapeutics completing its first cohort in an AML clinical trial is not available.",
      "banner_image": null,
      "source": "Investing.com South Africa",
      "category_within_source": "General",
      "source_domain": "Investing.com South Africa",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.905509"
        }
      ],
      "overall_sentiment_score": 0.014582,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.335132",
          "ticker_sentiment_score": "0.045380",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML - The Manila Times",
      "url": "https://www.manilatimes.net/2025/10/13/tmt-newswire/globenewswire/cero-therapeutics-announces-completion-of-first-cohort-of-phase-1-clinical-trial-of-cer-1236-in-aml/2199601",
      "time_published": "20251013T124440",
      "authors": [],
      "summary": "CERo Therapeutics has successfully completed the first cohort of its Phase 1 clinical trial for CER-1236, an investigational anti-LILRB4 antibody, in patients with acute myeloid leukemia (AML). The Data Monitoring Committee (DMC) approved dose escalation based on the safety and tolerability observed in the initial cohort. This marks a significant step forward in the development of CER-1236 as a potential new treatment for AML.",
      "banner_image": null,
      "source": "The Manila Times",
      "category_within_source": "General",
      "source_domain": "The Manila Times",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.942499"
        }
      ],
      "overall_sentiment_score": 0.006681,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.322361",
          "ticker_sentiment_score": "0.040638",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERo Therapeutics Advances Phase 1 Trial of CER-1236 Following Dose Escalation Approval, Clarifies Business Position - Quiver Quantitative",
      "url": "https://www.quiverquant.com/news/CERo+Therapeutics+Advances+Phase+1+Trial+of+CER-1236+Following+Dose+Escalation+Approval%2C+Clarifies+Business+Position",
      "time_published": "20251013T124400",
      "authors": [],
      "summary": "CERo Therapeutics announced the approval to initiate Cohort 2 of its Phase 1 clinical trial for CER-1236, an acute myeloid leukemia (AML) treatment, after successfully concluding Cohort 1 without dose-limiting toxicities. The company clarified that it is not for sale and not actively seeking partnerships, choosing instead to focus on advancing the clinical trial and gathering more data before exploring other strategic options. This decision comes after observations of consistent cell expansion with preclinical expectations, leading to an increased initial dosage for the next group of patients.",
      "banner_image": "https://www.quiverquant.com/images/cero_rect_new.png",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.648049"
        }
      ],
      "overall_sentiment_score": 0.002403,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.318842",
          "ticker_sentiment_score": "0.026448",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERo Therapeutics completes first cohort in AML clinical trial - Investing.com",
      "url": "https://www.investing.com/news/company-news/cero-therapeutics-completes-first-cohort-in-aml-clinical-trial-93CH-4284011",
      "time_published": "20251013T124221",
      "authors": [],
      "summary": "This article reports on an application error encountered while trying to access the news content from Investing.com. Therefore, no information is available regarding CERo Therapeutics or its AML clinical trial.",
      "banner_image": null,
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.915938"
        }
      ],
      "overall_sentiment_score": 0.0326,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.334253",
          "ticker_sentiment_score": "0.023213",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERo Therapeutics announces completion of first cohort of Phase 1 clinical trial of CER-1236 in AML - MarketScreener",
      "url": "https://www.marketscreener.com/news/cero-therapeutics-announces-completion-of-first-cohort-of-phase-1-clinical-trial-of-cer-1236-in-aml-ce7d5ad8df81f52c",
      "time_published": "20251013T123324",
      "authors": [
        "Reuters"
      ],
      "summary": "CERo Therapeutics Holdings, Inc. announced the completion of the first cohort of its Phase 1 clinical trial for CER-1236 in Acute Myeloid Leukemia (AML). The company is progressing with its clinical development, having recently dosed the third patient in the initial dose cohort and received FDA Fast Track Designation for CER-1236 in AML. This news highlights the ongoing advancements in CERo Therapeutics' pipeline for cancer treatment.",
      "banner_image": null,
      "source": "MarketScreener",
      "category_within_source": "General",
      "source_domain": "MarketScreener",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.443157"
        }
      ],
      "overall_sentiment_score": 0.038516,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.349247",
          "ticker_sentiment_score": "0.019576",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML - Stock Titan",
      "url": "https://www.stocktitan.net/news/CERO/ce-ro-therapeutics-announces-completion-of-first-cohort-of-phase-1-vwwwjymggnn3.html",
      "time_published": "20251013T123000",
      "authors": [],
      "summary": "CERo Therapeutics announced the completion of Cohort 1 of its Phase 1/1b clinical trial for CER-1236 in acute myeloid leukemia (AML), reporting in-vivo cell expansion and no dose-limiting toxicities. The Dose Escalation Safety Committee approved the initiation of Cohort 2 with an increased starting dose. CERo also stated it is not currently seeking acquisitions or partnerships, focusing instead on completing its dose-finding clinical activities.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.716232"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.423382"
        }
      ],
      "overall_sentiment_score": 0.034024,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.305260",
          "ticker_sentiment_score": "0.049357",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "D. Boral Capital Maintains CERo Therapeutics Holdings (CERO) Buy Recommendation",
      "url": "https://www.nasdaq.com/articles/d-boral-capital-maintains-cero-therapeutics-holdings-cero-buy-recommendation",
      "time_published": "20251013T080600",
      "authors": [
        "George Maybach"
      ],
      "summary": "D. Boral Capital has maintained its Buy recommendation for CERo Therapeutics Holdings (CERO) with an average one-year price target of $45.90/share, suggesting a significant upside of 1,282.53% from its latest closing price. Institutional ownership in CERO has also increased, with 12 funds reporting positions, reflecting growing sentiment. Parallel Advisors holds the largest stake with 18.25% ownership.",
      "banner_image": "NULL",
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.947967"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.848230"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.725976"
        }
      ],
      "overall_sentiment_score": 0.409115,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.403037",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia",
      "url": "https://www.globenewswire.com/news-release/2025/09/08/3146118/0/en/CERo-Therapeutics-Announces-Dose-Intensification-in-Phase-1-Study-of-CER-1236-in-Acute-Myeloid-Leukemia.html",
      "time_published": "20250908T084500",
      "authors": [],
      "summary": "CERo Therapeutics has intensified the dosage in its Phase 1 clinical trial for CER-1236 in acute myeloid leukemia (AML) patients, administering a second dose to the second patient with IRB authorization after initial positive pharmacokinetic data. This adjustment aims to evaluate the safety and feasibility of multiple infusions and increased dosing. Simultaneously, a study investigator presented the original trial protocol at a hematologic oncology conference, highlighting the company's progress and strengthening intellectual property.",
      "banner_image": "https://ml.globenewswire.com/media/MWNiNzZmZWMtNWUxYS00MTUzLTllMjktMmY2YTlhOTI1ODgyLTUwMDEyNDM5MC0yMDI1LTA5LTA4LWVu/tiny/CERo-Therapeutics-Holdings-Inc.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.405018,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.402272",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236",
      "url": "https://www.globenewswire.com/news-release/2025/06/23/3103364/0/en/CERo-Therapeutics-Holdings-Inc-Announces-First-Patient-Completes-Dose-Limiting-Toxicity-Observation-Period-with-No-Reported-DLTs-in-Phase-1-Trial-of-CER-1236.html",
      "time_published": "20250623T081500",
      "authors": [],
      "summary": "CERo Therapeutics Holdings, Inc. announced that the first patient in its Phase 1 clinical trial of CER-1236, a lead compound targeting TIM4L, completed the dose-limiting toxicity observation period with no reported toxicities. The Dose Escalation Safety Committee evaluated the patient, and the company plans to dose the second patient in the cohort shortly. This marks a significant milestone for the first-in-class biologic as CERo prepares to initiate a second trial for CER-1236 in solid tumors later this year.",
      "banner_image": "https://ml.globenewswire.com/media/OWZjNTllY2UtNTU1OS00NjEwLWFhNDUtODBhYzNhMzNlN2ZhLTUwMDEyNDM5MC0yMDI1LTA2LTIzLWVu/tiny/CERo-Therapeutics-Holdings-Inc.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.618717"
        }
      ],
      "overall_sentiment_score": 0.477326,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.465566",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Cero Therapeutics announces 1-for-20 reverse stock split",
      "url": "https://finance.yahoo.com/news/cero-therapeutics-announces-1-20-131531210.html",
      "time_published": "20250612T131531",
      "authors": [
        "TipRanks"
      ],
      "summary": "Cero Therapeutics announced a one-for-twenty reverse stock split, effective June 13, 2025. This action will reduce the number of outstanding shares from approximately 10.3 million to about 516,092 shares, with trading on a split-adjusted basis beginning the same day on The Nasdaq Capital Market.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.700130"
        }
      ],
      "overall_sentiment_score": -0.262188,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.282300",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split",
      "url": "https://www.globenewswire.com/news-release/2025/06/11/3097619/0/en/CERo-Therapeutics-Holdings-Inc-Announces-Reverse-Stock-Split.html",
      "time_published": "20250611T091000",
      "authors": [],
      "summary": "CERo Therapeutics Holdings, Inc. announced a one-for-twenty reverse stock split of its common stock, effective June 13, 2025, to begin trading on a split-adjusted basis on Nasdaq. This action will reduce outstanding shares from approximately 10.3 million to 516,092, with proportional adjustments to equity incentive plans and other securities. The company believes this facilitates compliance with Nasdaq listing standards and aims to advance its engineered T cell therapeutics for cancer treatment.",
      "banner_image": null,
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.908421"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.845164"
        },
        {
          "topic": "finance",
          "relevance_score": "0.706960"
        }
      ],
      "overall_sentiment_score": -0.424917,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.422361",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "CERo Therapeutics Holdings, Inc. Issues Additional Series D Preferred Stock Shares to Institutional Investors for Up to $8 Million",
      "url": "https://www.nasdaq.com/articles/cero-therapeutics-holdings-inc-issues-additional-series-d-preferred-stock-shares",
      "time_published": "20250606T082000",
      "authors": [
        "None for Quiver Quantitative"
      ],
      "summary": "CERo Therapeutics Holdings, Inc. has issued additional shares of Series D Preferred Stock to institutional investors, raising approximately $750,000, as part of a previous agreement for up to $8 million. These funds will support the company's clinical development efforts, particularly after receiving FDA IND allowances for liquid and solid tumors and for activating new research sites. While this demonstrates investor confidence and accelerates development, it may also lead to dilution for existing shareholders, and ongoing funding for future capital needs remains conditional on investor election.",
      "banner_image": null,
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.942388"
        },
        {
          "topic": "finance",
          "relevance_score": "0.830580"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.939342"
        }
      ],
      "overall_sentiment_score": -0.110018,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.102360",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Maxim Group Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy Recommendation",
      "url": "https://www.nasdaq.com/articles/maxim-group-initiates-coverage-cero-therapeutics-holdings-cero-buy-recommendation",
      "time_published": "20250519T200200",
      "authors": [
        "George Maybach for Fintel"
      ],
      "summary": "Maxim Group initiated coverage of CERo Therapeutics Holdings (CERO) with a Buy recommendation, leading to an analyst price target suggesting an 1,817.95% upside. Institutional ownership in CERO has significantly increased, with 20 funds now reporting positions and a substantial rise in total shares owned.",
      "banner_image": null,
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.921277"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.741537"
        }
      ],
      "overall_sentiment_score": 0.032044,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.344120",
          "ticker_sentiment_score": "0.041892",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERO Therapeutics\u2019 Stock Surge: What\u2019s Next?",
      "url": "https://stockstotrade.com/news/cero-therapeutics-holdings-inc-cero-news-2025_04_24/",
      "time_published": "20250424T102000",
      "authors": [
        "Tim Bohen",
        "Ben Sturgill",
        "Ellis Hobbs"
      ],
      "summary": "CERO Therapeutics (NASDAQ: CERO) stock surged by 46.36% following FDA approval for its second Investigational New Drug application for CER-1236, allowing it to proceed to Phase 1 clinical trials for major cancers. The company also secured two crucial patents for CER-1236 and an initial 'Buy' rating from D. Boral Capital with an $11 price target despite challenging financial metrics. This surge reflects investor confidence driven by strategic advancements in cancer therapy and intellectual property fortification.",
      "banner_image": null,
      "source": "StocksToTrade",
      "category_within_source": "General",
      "source_domain": "StocksToTrade",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.949284"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.903594"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.849734"
        }
      ],
      "overall_sentiment_score": 0.623383,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.641315",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "CERo Therapeutics Holdings, Inc. Announces $8 Million Securities Purchase Agreement to Advance Immunotherapy Development",
      "url": "https://www.nasdaq.com/articles/cero-therapeutics-holdings-inc-announces-8-million-securities-purchase-agreement-advance",
      "time_published": "20250422T082100",
      "authors": [
        "None for Quiver Quantitative"
      ],
      "summary": "CERo Therapeutics Holdings, Inc. has secured up to $8 million through a convertible preferred stock offering to fund the advancement of its immunotherapy development, particularly for its T cell therapies. The capital will support FDA IND allowances, activate clinical trial sites, and address Nasdaq deficiencies. CEO Chris Ehrlich highlighted investor support for the company's lead product candidate, CER-1236, as it moves towards clinical trials.",
      "banner_image": null,
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.927103"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.814027"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.744552"
        }
      ],
      "overall_sentiment_score": 0.401396,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.417655",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Cero Therapeutics to effect 1-for-100 reverse stock split",
      "url": "https://finance.yahoo.com/news/cero-therapeutics-effect-1-100-131313162.html",
      "time_published": "20250107T131313",
      "authors": [],
      "summary": "Cero Therapeutics announced its board of directors approved a one-for-one hundred reverse stock split of its common stock. This split will reduce the outstanding shares from approximately 260 million to 2.6 million and will take effect on January 8, 2025, with trading on a split-adjusted basis beginning the same day on The Nasdaq Global Market.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.938598"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.805938"
        }
      ],
      "overall_sentiment_score": -0.247596,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.214466",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia",
      "url": "https://finance.yahoo.com/news/cero-therapeutics-inc-receives-fda-134500755.html",
      "time_published": "20241115T134500",
      "authors": [],
      "summary": "CERo Therapeutics, Inc. announced that the FDA has cleared its Investigational New Drug (IND) Application for Phase 1 clinical trials of its lead compound, CER-1236, in acute myelogenous leukemia (AML). The company anticipates initiating the first-in-human trial in AML in the first quarter of 2025, aiming to explore the novel approach of its engineered T cell therapeutics. This milestone represents a significant step in the development of CERo's Chimeric Engulfment Receptor T cells (CER-T) platform, designed to enhance cancer therapy by integrating innate and adaptive immunity.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.906648"
        },
        {
          "topic": "finance",
          "relevance_score": "0.701206"
        }
      ],
      "overall_sentiment_score": 0.620349,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.634195",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    }
  ]
}